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Background: Dialysis patients suffer from a high burden of cardiovascular disease (CVD). Partly this is due to
progressive deterioration of calcium-phosphate homeostasis. Previous studies suggested that besides FGF-23, low
levels of Klotho, a protein linked to aging, might constitute a key factor in this detrimental relationship. The purpose
of the present study was to determine the relationship between serum Klotho (sKlotho) and the presence of CVD
in dialysis patients.
Methods: Plasma levels of sKlotho were measured in a cohort of dialysis patients and related to left ventricular (LV)
dysfunction (defined as a LV ejection fraction <45%) and LV mass using echocardiography. Coronary artery disease
(CAD) and calcification score were assessed using computed tomography angiography. Abdominal aortic
calcification score (AACscore) was measured by abdominal X-ray.
Results: We included 127 dialysis patients, 67 ± 7 years old, 76% male, 67% on hemodialysis, median sKlotho
460 pg/mL (25th-75th percentile 350-620 pg/mL). Patients with a low sKlotho (<460 pg/mL) showed significantly
more CAD (81% versus 61%; p = 0.02) and LV dysfunction (19% versus 3%; p < 0.01). However, after adjusting for
confounders, sKlotho was not independently associated with the presence of CVD or the AACscore.
Conclusions: In the present cohort of dialysis patients, sKlotho was not independently associated with CVD.
However, patients with a low sKlotho level (<460 pg/mL) did show CAD and LV dysfunction more frequently.
Therefore, while sKlotho might be a marker for CVD in dialysis patients, the current data does not support a direct
cardioprotective effect of sKlotho.
Keywords: End stage renal disease, Dialysis, Klotho, Cardiovascular diseaseBackground
Patients with chronic kidney disease (CKD) suffer from
a high burden of cardiovascular disease (CVD) [1,2].
Whereas part of this burden is related to traditional risk
factors, CKD associated disturbance in calcium-phosphate
homeostasis play a crucial role as well [3]. Recently,
Fibroblast growth factor-23 (FGF-23) and its co-receptor
Klotho have emerged as pivotal players in calcium-
phosphate homeostasis and they could be the missing* Correspondence: j.i.rotmans@lumc.nl
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unless otherwise stated.link in the detrimental relationship between CKD and
CVD [4].
Membrane-bound Klotho is a co-receptor for FGF-23
vital for FGF-23’s phosphaturic effect. In CKD serum
FGF-23 levels rise in response to phosphate retention,
while Klotho levels decrease [5]. Elevated FGF-23 levels
are associated with worse cardiovascular outcome but it
is unknown whether this is due to the toxic effect of
FGF-23 itself or due to Klotho deficiency causing a state
of FGF-23 resistance. Studies examining the relationship
between low Klotho and outcome show conflicting re-
sults [6,7].
Klotho was first identified in mice, where mutations of
the gene led to a syndrome resembling aging [8]. TheThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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soluble form (sKlotho). sKlotho is derived from the
extracellular part of membranous Klotho and through
alternative splicing of the Klotho gene and has a unique
role in renal calcium and phosphate excretion, inde-
pendent of FGF-23 [9-12]. Furthermore, sKlotho has
been associated with protective effects on vascular calcifi-
cation and oxidative stress in preclinical studies [13,14].
Since the kidneys are the principal source of sKlotho,
some studies have suggested that CKD might be a state of
progressive Klotho deficiency [15,16].
Given the strong cardioprotective effects of Klotho
demonstrated in preclinical studies, the current study
aimed to assess the association between sKlotho and
CVD in patients on chronic dialysis. It was hypothesized
that low levels of sKlotho are associated with a larger
burden of CVD in these patients.
Methods
Population and design
For this study, all patients enrolled in the ICD-2 trial
(ISRCTN 20479861) until January 2013 were analyzed.
The ICD-2 trial is an ongoing randomized controlled
trial designed to evaluate the effectiveness of an implant-
able cardioverter defibrillator in the prevention of sudden
cardiac death in dialysis patients. The study protocol has
been described previously [17]. The study population con-
sists of 55–80 year old patients with a left ventricular ejec-
tion fraction (LVEF) of at least 35%. All patients provided
written informed consent and the design of the trial was
approved by the local ethics committee (Leiden University
Medical Center, Leiden, the Netherlands).
An extensive screening protocol was performed in all
patients at the time of enrollment in the ICD-2 trial, in-
cluding blood analysis, computed tomography angiog-
raphy (CTA), transthoracic echocardiography (TTE) and
lateral abdominal X-ray. Furthermore clinical data on
demographic characteristics, coexisting conditions, use
of medications and information regarding the dialysis
procedures were collected. Twenty-four-hour urinary
samples were collected in all patients. Residual renal
function was calculated as the mean of creatinine and
urea clearance adjusted for body surface area (ml/min
per 1.73 m2). The mean of both post- and pre-dialysis
plasma samples (if available) were used to estimate mean
plasma creatinine and urea concentrations [18]. The re-
sidual renal function was considered zero in patients
with a urinary output <100 mL/24 hours.
Laboratory tests
After collection, the blood samples were immediately cen-
trifuged, separated in vials and stored at −60°C for future
essays. Serum levels of creatinine, calcium and phosphate
were measured at time of inclusion. Concentrations ofplasma c-terminal FGF-23, soluble serum Klotho (sKlotho),
serum 25-hydroxyvitamin D (25(OH)D) and plasma para-
thyroid hormone (PTH) were measured from the frozen
samples. FGF-23 was measured using an assay designed to
measure C-terminal FGF-23 (Immutopics, San Clemente,
CA, USA) [19]. For the measurement of sKlotho an ELISA
assay was used (IBL, International GmbH, Hamburg,
Germany) based on the antibodies and substrates de-
signed, used and described by Yamazaki and colleagues
(intra- and inter-assay coefficients of variation <5% and
8%) [20]. 25(OH)D levels were measured using a LC-MS/
MS method [21].
Echocardiography
All patients underwent 2-dimensional TTE with com-
mercially available ultrasound equipment (M3s probe,
Vivid 7, GE Vingmed, Horton, Norway). The images
were digitally stored for off-line analysis (EchoPAC version
110.0.0, GE Vingmed, Horten, Norway). Using Simpson’s
biplane method, left ventricular mass index (LVMI) and
LVEF were assessed by a single independent observer. In
accordance with the current guidelines, LV dysfunction
was defined as a LVEF < 45% [22].
Multi slice CT protocol
The CTA protocol used has been previously described
[23]. Patients were scanned using a 64-slice CT scanner
(Aquillion64, Toshiba Medical Systems, Otawara, Japan)
or a 320-slice CT scanner (Aquilion ONE, Toshiba Med-
ical Systems, Otawara Japan). In the presence of residual
renal function, post and prehydration were performed
in accordance with the nephrologist. The coronary artery
calcium score (CACscore) was analyzed using the Agat-
ston method [24]. The presence of significant coronary
artery stenosis was defined as ≥50% luminal narrowing.
Coronary artery disease (CAD) was defined as the pres-
ence of at least one coronary artery with stenosis. If cor-
onary artery bypass grafting or a percutaneous coronary
intervention was performed in the past, treated vessels
were scored as occluded and the native vessels scored
using CTA.
Quantification of abdominal aortic calcification
The extent of aortic calcification was calculated on a lat-
eral X-ray of the abdomen. This X-ray was taken in a
standing position using standard radiographic equip-
ment. The abdominal aorta calcification (AAC) score
was calculated using a previously validated grading sys-
tem, in which the extent of calcific deposits in the ab-
dominal aorta is graded on a per segment basis [25].
Statistical analysis
Continuous data are presented as mean ± SD and com-
pared using the 2-tailed Student’s t-test. Categorical data







n = 127 n = 63 n = 64
Age, years 67 ± 7 67 ± 7 67 ± 8
Gender, female 30 (24%) 10 (16%) 20 (31%)*
Pulse pressure, mmHg 59 ± 24 59 ± 24 59 ± 16
Hypertension 104 (82%) 53 (87%) 51 (80%)
Diabetes 43 (34%) 24 (40%) 19 (30%)
Dialysis Modality, PD 42 (33%) 8 (13%) 34 (53%)***
Dialysis vintage, years 2.3 ± 2 2.6 ± 2.7 2.0 ± 2.2
RRF, (ml/min/1.73 m2) 1.8 ± 1.6 1.7 ± 1.8 2.0 ± 1.4
Anuria 30 (24%) 20 (33%) 10 (16%)*
Phosphate (mmol/L) 1.5 ± 0.4 1.6 ± 0.4 1.5 ± 0.4
Calcium (mmol/L) 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.2
FGF-23 (RefU/mL) 7247 ± 16815 8723 ± 21627 5794 ± 10044
25(OH)D (nmol/L) 87 ± 57 102 ± 65 71 ± 42**
PTH (pmol/L) 35 ± 34 42 ± 41 28 ± 22*
Creatinine (umol/L) 659 ± 202 642 ± 211 676 ± 195
CRP (mg/L) 14.3 ± 30.7 20.1 ± 41.7 8.9 ± 12.22*
β -blocker 71 (56%) 37 (60%) 34 (54%)
ACEi 32 (25%) 19 (31%) 13 (21%)
ARB 37 (29%) 13 (21%) 24 (38%)*
Statin 79 (62%) 43 (69%) 36 (57%)
NCPB 107 (84%) 54 (87%) 53 (84%)
CCPB 50 (39%) 25 (40%) 25 (40%)
Cinacalcet 15 (12%) 7 (12%) 8 (13%)
PD; Peritoneal dialysis, RRF; Residual Renal Function, FGF-23; Fibroblast Growth
Factor 23. PTH; Parathyroid hormone, ACEí; Angiotensin Converting Enzyme
inhibitor, ARB; Angiotensin receptor blocker, NCPB; Non calcium containing
phosphate binder, CCPB; Calcium containing phosphate binder. *;p < 0.05,
**;p < 0.01; ***;p < 0.001.
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pared using the Chi-square test. For the initial data pres-
entation, the cohort was divided into two groups using
median sKlotho as a cut-off.
The relationship between sKlotho and CVD was ex-
plored using regression models. For the AACscore,
CACscore and LVMI linear regression models were used
with unstandardized Beta’s and a 95% confidence inter-
val (CI). To assist practical usability of the models,
sKlotho was transformed from 1 pg/mL to 100 pg/mL,
thus Beta’s represent changes of 100 pg/mL sKlotho. For
the association between sKlotho and CAD as well as LV-
dysfunction, logistic regression models were used. Nor-
mality, linearity and homoscedasticity of the different
variables in relation to sKlotho were checked. If residuals
were not normally distributed, a logarithmic transform-
ation (ln) was performed. In both the linear and logistic
regression analysis, two models were used; model 1;
crude model and model 2; additionally adjusting for po-
tential confounders: age, gender, dialysis type, dialysis vin-
tage and residual renal function (mL/min per 1.73 m2).
The correlations between the different parameters in
the calcium-phosphate metabolism and sKlotho levels
were evaluated using a Spearman rank correlation test.
In a method comparable to the one used for sKlotho,
the relationship between FGF-23 and CVD (AACscore,
CACscore, LVMI, CAD and LV-dysfunction) was ex-
plored using regression models adjusting for potential
confounders. To assess a possible combined effect of
sKlotho and FGF-23 we compared patients with a high
suspected calcification risk (low sKlotho and high FGF-
23) to patients with a low suspected calcification risk
(high Klotho and low FGF-23) based on the median of
sKlotho and FGF-23.
All statistical analyses were performed using SPSS (ver-
sion 20, IBM Corp, Amonk, NY, USA). A p-value <0.05
was considered statistically significant.
Results
Patient characteristics
A total of 127 patients were included for the current
study. The average age of the participating patients was
67 ± 7 years, 24% was female and 68% utilized hemo-
dialysis (HD) as modality for renal replacement therapy.
Median sKlotho was 460 pg/mL (25th-75th percentile;
350-620 pg/mL). The baseline characteristics are shown in
Table 1. The cause of end stage renal disease (ESRD) was
hypertension (24%), diabetes (18%), glomerulonephritis
(9%), acute tubular necrosis (5%) and other (22%) or un-
known causes (22%).
After stratifying patients for plasma sKlotho levels
into two groups, patients with a high sKlotho (>460 pg/
mL) were more often female (31% versus 16%; p = 0.04),
more often had residual renal function (84% versus 67%;p = 0.04), more frequently utilized peritoneal dialysis (PD;
53% versus 13%; p < 0.001) and more often used an angio-
tensin receptor blocker (ARB; 38% versus 21%; p = 0.04).
Patients with a low sKlotho had a higher plasma 25(OH)D
(102 nmol/L versus 71 nmol/L; p = 0.002), PTH (42 pmol/
L versus 28 pmol/L; p = 0.02) and CRP (20.1 mg/L versus
8.9 mg/L; p = 0.04) (Table 1). No further differences in
baseline characteristics were found between the two
groups.
sKlotho and markers for cardiovascular disease
In the 127 included patients, the average AACscore was
9 ± 6, mean CACscore was 1134 ± 1316 and the average
LVMI was 128 ± 42 g/m2. A total of 76 (60%) patients
suffered from CAD and 13 patients (10%) had LV dysfunc-
tion. As described in the method section, only patients
with LVEF ≥ 35% were included in the study. Patients with
a high sKlotho (>460 pg/mL) had significantly less CAD
Table 2 Association between sKlotho and cardiovascular
disease
AACscore Beta CI p-value
Model 1. Crude association 0.33 −0.26–0.91 0.27
Model 2. (+ Confounders)* 0.58 −0.07–1.22 0.08
CACscore Beta CI p-value
Model 1. Crude association −0.06 −0.31–0.20 0.66
Model 2. (+Confounders)* 0.08 −0.19–0.36 0.55
LVMI Beta CI p-value
Model 1. Crude association −1.27 −5.58–3.04 0.56
Model 2. (+Confounders)* 1.55 −3.49–6.60 0.54
LV-dysfunction (LVEF < 45%) OR CI p-value
Model 1. Crude association 0.58 0.37–0.92 0.02
Model 2. (+Confounders)* 0.66 0.39–1.11 0.12
CAD (any vessel occluded) OR CI p-value
Model 1. Crude association 0.82 0.65–1.05 0.11
Model 2. (+Confounders)* 0.91 0.66–1.23 0.52
Beta’s represent changes of 100 pg/mL in sKlotho.
AACscore; Abdominal aorta calcification score, CACscore; Coronary artery
calcification score, LVMI; Left ventricular mass index, LV-dysfunction; Left
ventricular dysfunction. CAD; Coronary artery disease.
Model 1; sKlotho. *Model 2; + age, gender, (ln)dialysis vintage, dialysis type,
residual renal function.
Table 3 Spearman correlation coefficients of parameters
of calcium-phosphate metabolism and sKlotho levels
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less LV dysfunction (3% versus 19% of patients; p = 0.006).
The other markers for CVD were not significantly differ-
ent between both groups.
The results of the multivariate regression modelling,
with the different markers for CVD as dependent vari-
ables are shown in Table 2. In model 1, the crude associ-
ation between sKlotho and numerous markers for CVD
was assessed. In these first models, sKlotho was not sig-
nificantly associated with AACscore, CACscore, LVMI
or the presence of CAD. However, a statistically signifi-
cant crude association between sKlotho and the pres-
ence of LV-dysfunction was observed (OR: 0.58; 95% CI
0.37-0.92; p = 0.02). In model 2 the association between
sKlotho and CVD was assessed after adjusting for con-
founders (age, gender, (ln)dialysis vintage, dialysis type
and residual renal function). After the adjustments made
in model 2, sKlotho showed no significant association
with any of these investigated markers for CVD.
sKlotho and markers of the calcium-phosphate axis
The associations between the different parameters in the
calcium-phosphate axis are shown in Table 3. Serum
sKlotho level was significantly associated with a lower
plasma 25(OH)D (r = −0.22, p = 0.01) and lower PTH
(r = −0.26; p < 0.01). FGF-23 showed a strong positive as-
sociation with phosphate level (r = 0.51; p < 0.001) and
PTH r = 0.30; p < 0.001). There was no crude association
between serum FGF-23, PTH, 25(OH)D or phosphate and
any of the investigated markers for CVD (data not shown).
Furthermore, in the different multivariate regression models,
FGF-23 was not independently associated with CVD after
adjusting for confounders (Although a LVEF < 45% showed
a trend toward an independent association with FGF-23,
OR: 0.51 (0.26-1.00; p = 0.053, Table 4).
A total of 26 patients had a high median serum FGF-23
(>2625 RefU/L) combined with a low sKlotho (<460 pg/
mL), compared to 26 patients with a low FGF-23 (<2625Figure 1 Serum Klotho and the number of occluded coronary
arteries. Number of occluded coronary arteries in patients with low
sKlotho versus patients with high sKlotho.RefU/L) and high sKlotho level (>460 pg/mL). Patients in
the former group had a significantly higher CACscore
(1242 ± 1037 versus 485 ± 656; p = 0.01) as well as a trend
towards lower LVEF (52 ± 7% versus 55 ± 6%; p = 0.07)
and more CAD (85% versus 60%; p = 0.07).
Discussion
Recently, sKlotho has emerged as a powerful player in
calcium-phosphate homeostasis that is thought to con-
tribute to the high burden of CVD in CKD patients [4].
To the best of our knowledge, the present study is the
first study that investigated the association betweenPhosphate 25(OH)D PTH FGF-23 sKlotho
(mmol/L) (nmol/L) (pmol/L) (RefU/L) (pg/mL)
25(OH)D r = 0.06
(nmol/L) p = 0.53
PTH r = 0.30 r = −0.01
(pmol/L) p < 0.01 p = 0.90
FGF-23 r = 0.51 r = −0.03 r = 0.29
(RefU/L) p < 0.001 p = 0.76 P = 0.001
sKlotho r = −0.04 r = −0.22 r = −0.26 r = 0.11
(pg/mL) p = 0.64 p = 0.01 p < 0.01 p = 0.22
Calcium r = 0.04 r = 0.05 r = −0.09 r = 0.22 r = −0.04
(mmol/L) p = 0.67 p = 0.55 p = 0.34 p = 0.01 p = 0.66
PTH; Parathyroid hormone, FGF-23; Fibroblast Growth Factor 23. Indicated are
correlation coefficients (r) with levels of significance (p).
Table 4 Association between FGF-23 and cardiovascular
disease
AACscore Beta CI p-value
Model 1. Crude association 0.72 −0.13-1.57 0.10
Model 2. (+ Confounders)* 0.49 −0.35-1.34 0.25
CACscore Beta CI p-value
Model 1. Crude association 0.25 −0.13-0.63 0.20
Model 2. (+Confounders)* 0.001 −0.40-0.40 1.00
LVMI Beta CI p-value
Model 1. Crude association 0.48 −5.79-6.75 0.88
Model 2. (+Confounders)* −0.70 −7.40-6.00 0.84
LV-dysfunction (LVEF < 45%) OR CI p-value
Model 1. Crude association 0.68 0.40-1.16 0.16
Model 2. (+Confounders)* 0.51 0.26-1.01 0.053
CAD (any vessel occluded) OR CI p-value
Model 1. Crude association 0.94 0.66-0.63 0.20
Model 2. (+Confounders)* 0.65 0.41-1.04 0.08
Beta’s represent changes in LnFGF-23.
AACscore; Abdominal aorta calcification score, CACscore; Coronary artery
calcification score, LVMI; Left ventricular mass index, LV-dysfunction; Left
ventricular dysfunction. CAD; Coronary artery disease.
Model 1; sKlotho. *Model 2; + age, gender, (ln)dialysis vintage, dialysis type,
residual urine production.
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hypothesis, while patients with a low sKlotho demon-
strated LV dysfunction and CAD more often, there was
no independent association between sKlotho and CVD
in the present cohort.
sKlotho and cardiovascular disease
Several clinical studies have suggested that Klotho exerts
strong cardioprotective effects. For instance, Klotho has
been shown to protect against vascular calcifications in
rodent models of CKD while in humans without CKD,
higher sKlotho levels have been related to a lower inci-
dence of mortality and CVD [8,9,26,27]. Moreover, low
sKlotho levels have been associated with increased arter-
ial stiffness in CKD patients [28]. Further support for a
direct role of Klotho in vascular homeostasis comes
from in vitro studies showing endogenous expression of
Klotho in human vascular smooth muscle cells (VSMCs)
[14]. Interestingly, inhibition of sKlotho expression in
aortic VSMCs resulted in accelerated calcification of
these cells [14]. However, the exact role of Klotho in the
progression of CVD in dialysis patients remains to be
elucidated.
In the present study, dialysis patients with a low sKlotho
demonstrated LV-dysfunction and CAD more frequently.
However, an independent association between sKlotho
and CVD was not observed. There are several possible ex-
planations for these findings.
First, disorders of mineral homeostasis, as well as
CVD start to develop in the early stages of CKD [1,3].Therefore, patients with ESRD have been exposed to an
environment predisposing to vascular calcifications for a
prolonged period of time. In our study, we solely mea-
sured sKlotho levels at time of inclusion and as a conse-
quence, the sKlotho levels in our study do not reflect
the total ‘burden’ of Klotho deficiency in the dialysis pa-
tients’ preceding years with CKD. Thus, the association
between sKlotho and vascular pathology might be di-
minished by the time patients have developed ESRD.
Second, the role of sKlotho in the development of ath-
erosclerotic disease in dialysis patients might be oversha-
dowed by the large amount of other pathophysiological
stimuli for CVD prevalent in these patients, such as smok-
ing, obesity, diabetes and hypertension among others. This
might explain the disparity between data found in rodents
with only Klotho deficiency and patients suffering from a
wide variety of co-morbidities [8,9].
A third explanation could be that sKlotho simply has
no independent contribution to CVD in dialysis patients.
Several very recent publications revealed similar results
[29-32]. In patients with CKD up to stage IV, sKlotho
was not associated with AACscore nor was it predictive
for cardiovascular outcomes [29,30]. In addition, pre-
clinical studies have provided for a limited role of Klotho
in the vasculature since they showed a very low or ab-
sent vascular Klotho expression and Klotho mediated ef-
fects in human and murine VSMCs [31,32].
Even though sKlotho does not appear to be independ-
ently associated with CVD in dialysis patients in the
present study, CAD and LV dysfunction was more often
present in patients with a low sKlotho level. Further-
more, patients with a combination of low serum sKlotho
and high FGF-23 showed a significantly higher CAC-
score as well as a trend toward a lower LVEF and less
CAD. Therefore, sKlotho might be an effective bio-
marker for CVD. In this respect, it would be interesting
to explore the association between urinary sKlotho and
CVD, since recent studies have illustrated that urinary
sKlotho might correlate better with renal function that
plasma sKlotho [33].
Effect of treatment modalities on sKlotho level
In the investigated cohort two interesting observations
were made regarding the association between treatment
modalities and sKlotho levels. In line with a previous
study that showed that losartan increased sKlotho levels,
we observed that patients with a higher sKlotho more
often used an ARB [34]. It was observed in rats that ad-
ministration of angiotensin-II reduced Klotho gene ex-
pression at both mRNA and protein level in the kidney,
whereas ARB and renin inhibitors increased Klotho ex-
pression [35,36]. These studies suggest a direct inhibi-
tory effect of the renin-angiotensin-aldosterone system
(RAAS) on Klotho expression [37].
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sKlotho more often performed PD. This is an intriguing
difference, since sKlotho is excreted in the peritoneal di-
alysate (median amount of 114 ng/day), while the mo-
lecular weight of sKlotho is too high (120–130 kDa) to
allow clearance by hemodialysis [38]. A possible explan-
ation could be that the higher residual renal function in
PD patients as observed in our cohort, reflects a health-
ier kidney and thus higher sKlotho levels.
Limitations
This study has some limitations. Data on dietary phos-
phate intake was not collected, which is a known deter-
minant for both serum phosphate and FGF-23 levels.
Furthermore sKlotho was not measured at a fixed time
and thus a circadian variation in the measured sKlotho,
as described in previous studies, cannot be excluded [39].
However, all blood samples in the ICD-2 trial were taken
in the morning, somewhat decreasing this variability.
Conclusions
In the present cohort of dialysis patients, sKlotho level
was not independently associated with cardiovascular dis-
ease. However, patients with a low sKlotho level (<460 pg/
mL) did show CAD and LV dysfunction more often.
Therefore, while sKlotho might be a marker for CVD in
dialysis patients, the current data does not support a direct
cardioprotective effect of sKlotho.
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